Asset
POCIREDIR
FULCRUM THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07401823 | phase2 | enrolling_by_invitation | 2026-03-30 | 2030-02-04 | Fulcrum Therapeutics | Open-Label Extension Study to Pioneer Study 6058-SCD-101 |
| NCT04586985 | phase1 | completed | 2020-10-26 | 2022-11-15 | Fulcrum Therapeutics | Safety, Tolerability and Pharmacokinetics of FTX-6058 |
| NCT05169580 | phase1 | completed | 2021-12-13 | 2026-01-20 | Fulcrum Therapeutics | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir |
| NCT07431398 | phase1 | terminated | 2025-12-13 | 2026-06-01 | Fulcrum Therapeutics | Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease |
FDA applications (0)
This company has no applications containing this asset.